fda approved glp-1 New Pill Foundayo (Orforglipron) Gets Approval for Obesity FDA approval for first generic

Unlike Ozempic and Wegovy, which primarily focus on GLP-1, Mounjaros unique approach improves insulin secretion while reducing glucagon production

Fu Z, Mui D, Zhu H, Zhang Y

Consider semaglutide if: You prioritize lower cost and established safety data You have a history of GI sensitivity and prefer gradual titration You want to start with the more affordable option (semaglutide at $299/month) You're seeking 15-18% weight loss with solid cardiovascular benefit Consider tirzepatide if: You have more aggressive weight loss goals (20%+ reduction) You have type 2 diabetes or significant cardiometabolic risk Cost is not a primary barrier You tolerate GI side effects well or are willing to manage them Many patients find success on either medication

Providers manage GLP-1 titration based on response, side effects, and progress

Dose Range: 100300 mcg of each peptide daily with gradual titration

Brosnan JT